TaiMed Biologics Inc (中裕新藥) remained in the red last quarter, despite strong sales of its new drug Trogarzo, due to the continued high cost of research and development (R&D).
The company yesterday reported a net loss of NT$323.02 million (US$10.62 million) in the third quarter, down 9.2 percent year-on-year, or losses per share of NT$1.28.
Even though revenue grew 189 percent annually to NT$211 million thanks to robust sales of the HIV treatment drug Trogarzo in the US, the NT$271.96 million expense of developing a processing system for new contract manufacturing partner Samsung BioLogics Co has dented the company’s profitability.
The South Korean-based Samsung BioLogics is expected to begin production of Trogarzo at a new plant by next year at the earliest, TaiMed chief financial officer Jack Chen (陳怡成) said.
The new system and larger equipment are needed, as the new partner’s scale of production is to be seven times greater than TaiMed’s current manufacturing partner, WuXi Biologics Co (無錫生物製藥), Chen said.
The higher R&D expense is necessary and would benefit TaiMed in the long run, it said.
“Without the investment, we might have gotten out of the red by now, but it would be for nothing as TaiMed, a company focusing on new drugs, must keep devoting resources to R&D,” chief technology officer Jimmy Chang (張金明) said.
TaiMed holds a stake in the Montreal-based Theratechnologies Inc, its exclusive marketing and distributing partner in more than 30 markets, but was forced to report a nonoperating loss of NT$74 million last quarter after the partner’s share price dropped.
Overall, net losses for the first nine months of the year increased 194 percent from a year earlier to NT$495 million, or losses per share of NT$1.97.
Even though TaiMed has not turned a profit, the rise in revenue has enabled the firm to continue developing other new drugs such as TMB-365, TMB-Bispecific and VRC07-523LS, which are used to treat HIV and prevent infections, and are still in phase I clinical trials, Chang said.
Unlike Trogarzo, which is a fourth-line treatment and an alternative for patients with multi-drug resistance, the three new drugs would be used as second-line treatments, meaning that more patients could take them at an earlier stage, he said.
TaiMed expects the phase III clinical trials for the intravenous infusion formulation of TMB-355, a key ingredient in Trogarzo, to be completed in the first quarter of next year, Chang said, adding that the firm continues to work toward its goal of gaining marketing approval for the product by next year.
Gross margin recovered from 17 percent in the first half of this year to 47 percent last quarter as production yield at WuXi Biologics has improved, Chen said, adding that gross margin is expected to remain between 40 and 50 percent this quarter.
‘ACCORDING TO PLAN’: A company official said that it has set up production sites worldwide to provide services and that its Wisconsin project was going smoothly Hon Hai Precision Industry Co’s (鴻海精密) smart manufacturing center in Wisconsin would begin trial manufacturing in the middle of this year, the company said yesterday, adding that it plans to build a research institute to develop key technologies to support growth over the next five years. Hon Hai, known internationally as Foxconn Technology Group (富士康科技集團), said in an annual report submitted to the Taiwan Stock Exchange that its planned Foxconn Institute for Research in Science and Technology would conduct research into artificial intelligence, next-generation communications, quantum computing, cybersecurity and nano semiconductors in Taiwan. Hon Hai is to make products at the center
STAYING AHEAD: Fitch said that TSMC remains technologically ahead of others, but Samsung is building a new chip fab, while China is investing in its domestic industry As escalating US-China tensions and COVID-19-related production disruptions force US technology supply chains to transform, Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) US$12 billion chip fabrication plant in Arizona would be key to spurring greater US production of core semiconductor components, Fitch Ratings said. “We view the US-TSMC alliance as a first step in building a more autonomous US technology supply chain, given high barriers to entry, specifically related to the significant capital and design capability required for leading-edge semiconductor manufacturing,” Fitch said in a statement on Tuesday. “By working with TSMC, US chipmakers will not face the financial burden of incremental investment
E Ink Holdings Inc (元太科技), the world’s sole supplier of e-paper displays for e-readers and shelf labels, posted its best quarterly net profit for the first quarter in nine years amid increased demand during a traditionally slow season. Net profit soared 80 percent to NT$787 million (US$26.23 million) in the quarter ended March 31, compared with NT$438 million a year earlier. That translated into earnings per share of NT$0.69, up from NT$0.39. E Ink posted lower royalty income of NT$371.23 million last quarter from NT$448.74 million a year earlier, a company financial statement showed. E Ink said that it expects royalty income to
DIVERSIFICATION: Although COVID-19 would push more companies to produce in emerging markets, DBS said that it was unlikely that firms would totally leave China Geopolitical tensions and supply disruptions are expected to accelerate the migration of manufacturing out of China, as concerns about the risk of production concentrated in one country increase, S&P Global Ratings said. Although its economic expansion might be weaker than previous levels due to the accelerated relocation of manufacturing, China’s economic growth would still be stronger than that of most other economies, the ratings agency said. “While absolute growth rates will moderate, we believe China’s economic performance will continue to be a key sovereign credit support,” S&P Global Ratings credit analyst Tan Kim Eng (陳錦榮) said in a statement on Thursday. “Its growth